Loading...
Derniers dépôts
-
-
Claire Bordat, Charlotte Cuerq, Charlotte Halimi, Donato Vairo, Emilie Blond, et al.. Carotenoids in familial hypobetalipoproteinemia disorders: Malabsorption in Caco2 cell models and severe deficiency in patients. Journal of clinical lipidology, 2024, 18 (1), pp.e105-e115. ⟨10.1016/j.jacl.2023.10.010⟩. ⟨hal-04694626⟩
-
-
-
-
-
-
-
-
Stéphane Paul, Nicolas Williet, Stéphane Nancey, Pauline Veyrard, Gilles Boschetti, et al.. No Difference of Adalimumab Pharmacokinetics When Dosed at 40 mg Every Week or 80 mg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose Intensification. Digestive Diseases and Sciences, 2020, 66, pp.2744 - 2749. ⟨10.1007/s10620-020-06567-x⟩. ⟨hal-04872701⟩
-
-
Bénédicte Caron, Philippe Seksik, Anthony Buisson, Pauline Wils, Guillaume Savoye, et al.. Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID. Therapeutic Advances in Gastroenterology, 2024, 17, pp.17562848241265776. ⟨10.1177/17562848241265776⟩. ⟨hal-04671762⟩
-
Guillaume Bouguen, Laure Gossec, Véred Abitbol, Eric Senbel, Guillaume Bonnaud, et al.. Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study. BioDrugs, 2024, 38 (6), pp.867-878. ⟨10.1007/s40259-024-00681-2⟩. ⟨hal-04719779⟩
-
Lucas Guillo, Mathieu Uzzan, Laurent Beaugerie, Jean-Marc Gornet, Aurélien Amiot, et al.. Impact of HIV Infection on the Course of Inflammatory Bowel Disease and Drug Safety Profile: A Multicenter GETAID Study. Clinical Gastroenterology and Hepatology, 2022, 20 (4), pp.787-797.e2. ⟨10.1016/j.cgh.2020.12.023⟩. ⟨hal-04168380⟩
-
Nombre de documents
48
Nombre de notices
127
Répartition par type de documents
Evolution